|
We asked 40 pharma leaders, who should be driving universal anticounterfeiting solutions?
| Pharma |
48% |
| Regulators |
43% |
| Vendors |
9% |
 |
|
|
|
|
|
|
|
|
10 April, 2012 |
|
| In this Issue |
IP: Time for a Reset?
IP must adapt to new ways of extracting value from assets the industry never knew it had, beginning with a more robust defense of data exclusivity, writes William Looney
Read more... |
Brazil's Rapidly Growing Generics Market
Brazil’s generic-drug market grew by 32.2% in terms of sales volume between 2010 and 2011 alone, reaching R$8.7 billion (approximately US $5.05 billion). The country sold 581 million units of generic drugs in 2011 compared with 439 million units sold the previous year.Additional innovator patents are expected to expire by 2017, including Pfizer's ziprasidone and Wyeth’s sirolim. More... |
 |
A Cautionary Note for Developers of Personalized Medicine
A recent high-profile cancer study conducted at Duke University relied on genomic analysis of tumors to tailor treatment to individual patients. But questions about the validity of the tests were raised at the outset of the trials. Amy Ritter reports. More... |
US: Obamacare's Effect on Drug Spending
Provisions in the US’s Affordable Care Act drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year olds in 2011, according to IMS research published on last week. More...
|
| Case Study |
Reducing outsourcing costs and cycle-times
 Discover how a biotech saved $600,000 on a Phase II contract, compressed the contracting cycle-time from three months to two weeks, and formed a more constructive and collaborative working relationship with their CRO.
 Download the case study today.
|
|
|
|
|
|
|
